Reunion Neuroscience Inc T.REUN

Healthcare Biotechnology

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

TSX:REUN - Post by User

Reunion Neuroscience Inc > Fieldtrip

<< Previous

Bullboard Posts

Next >>

Comment by evilballson Feb 12, 2021 2:03am

245 Views

Post# 32549435

RE:RE:Fieldtrip

The warrants. Someone needs to buy the warrants. I know they haven't been listed long but geez... stock closes at $2.40 in the money but the warrants close at $1.80... Should be $2.40 plus a premium. I am a long term holder so its an end of day balance I know but those warrants are very cheap. they need a market maker lol.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity